A detailed history of Helen Stephens Group, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Helen Stephens Group, LLC holds 2,107 shares of ABBV stock, worth $459,410. This represents 0.11% of its overall portfolio holdings.

Number of Shares
2,107
Previous 1,316 60.11%
Holding current value
$459,410
Previous $244,000 99.59%
% of portfolio
0.11%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 02, 2025

BUY
$184.85 - $231.54 $146,216 - $183,148
791 Added 60.11%
2,107 $487,000
Q2 2025

Jul 02, 2025

SELL
$170.16 - $206.27 $1,701 - $2,062
-10 Reduced 0.75%
1,316 $244,000
Q1 2025

Apr 23, 2025

SELL
$169.2 - $216.66 $7,275 - $9,316
-43 Reduced 3.14%
1,326 $277,000
Q4 2024

Jan 15, 2025

BUY
$164.99 - $203.87 $10,064 - $12,436
61 Added 4.66%
1,369 $243,000
Q3 2024

Oct 08, 2024

BUY
$163.84 - $199.33 $214,302 - $260,723
1,308 New
1,308 $258,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $386B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Helen Stephens Group, LLC Portfolio

Follow Helen Stephens Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Helen Stephens Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Helen Stephens Group, LLC with notifications on news.